Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease.

By Adam R. Williams, J. Hare. Circulation Research, 2011

868 citations recorded by the source corpus.

Subfields: Biomaterials, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/850bfac225c44e662b8456f1f57d25ec8a3251ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. Chaomei Chen
2. Meen Chul Kim
3. Rachael Dubin
4. J. Karp

In Genetics

1. Chaomei Chen
2. J. Karp

In Surgery

1. Chaomei Chen
2. Meen Chul Kim
3. Rachael Dubin
4. J. Karp

Citations in the corpus

• Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy (2012, background): “Several mechanisms of action underlying the ability of MSCs to produce reverse remodeling in chronically scarred ventricles can be inferred from preclinical studies.(40,41) Mesenchymal stem cells engraft and persist for several months in myocardium when delivered by TESI(31-33,42) and exert a range ”
• Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease (2012, background): “Despite evidence of preferential accumulation of MSCs at sites of myocardial ischemia (Williams and Hare, 2011), exogenously administered MSCs show poor survival and do not persist at the site of AMI (Iso et al., 2007; Terrovitis et al., 2010), probably because of the harsh ischemic…”
• Emerging trends and new developments in regenerative medicine: a scientometric update (2000 – 2014) (2014, background): “22 Williams and Hare 2011 Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease CIRC RES [77]”